(Q57949267)

English

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

scientific article published on 12 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

0 references

1 reference

based on heuristic

inferred from title

phase II clinical trial

1 reference

based on heuristic

inferred from title

interferon alfa

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

Frederic Rolland

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Sylvie Négrier

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Gwenaëlle Gravis

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

David Pérol

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Christine Chevreau

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Rémy Delva

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Ellen Blanc

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Céline Ferlay

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Lionnel Geoffrois

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Eric Legouffe

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Emmanuel Sevin

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Brigitte Laguerre

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Jacques-Olivier Bay

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Bernard Escudier

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

12 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

673-680

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance to targeted therapy in renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II designs.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Design issues of randomized phase II trials and a proposal for phase II screening trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternate endpoints for screening phase II studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted agents: the rules of combination

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Adverse effects of anticancer agents that target the VEGF pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiangiogenic agents and late anastomotic complications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

From theoretical synergy to clinical supra-additive toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential use of targeted agents in the treatment of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970124-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy for advanced renal cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

10.1016/S1470-2045(11)70124-3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21664867%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57949267&oldid=2040521861"